List view / Grid view
10 May 2017 | By DiscoverX
The goal of this webinar is to illustrate how knowledge of MrgX2 activity across a panel of mammalian species can be integrated into drug development to influence choice of compound, species model and dosing regimen...
Among the more than 60,000 US children who develop autism spectrum disorders (ASD) every year, 20,000 become nonverbal or lose the ability to speak. The numbers are similar in Europe and this nonverbal group will have to rely on assisted living for the rest of their life.
Draper's Joe Charest explains how synthetic organoids can lead to safer drug testing, and why organ-on-a-chip technology is the future of drug discovery...
Mundipharma EDO GmbH's Dr Thomas Mehrling talks through the benefits of streamlining the drug discovery and development process using the EDO model...
Although anti-inflammatory treatments are quite effective at reducing symptoms in patients with Crohn's disease and ulcerative colitis, the mucosal lining of the intestine often remains ulcerated, and many patients still ultimately require surgery.
Charles River Laboratories today announced that it has extended its longstanding, strategic, integrated drug discovery partnership with Chiesi Farmaceutici SpA in the field of respiratory disease...
HTS can be carried out in a number of formats, ranging from simple biochemical (target-based) to whole animal screening assay formats. Horst Flotow, from Hit Discovery Constance, discusses the benefits and practicalities of, and recent progress in, whole animal screening. Madhu Lal-Nag, National Center for Advancing Translational Sciences, and Anton…
Drug developers sometimes think of imaging as an emerging discipline. But John Waterton, Paul Hockings, Juliana Maynard and Caleb Roberts explain how imaging biomarkers are transforming drug development. Francesco Gatto and Jens Nielsen, from the Chalmers University of Technology in Sweden, discuss moving towards systems biomarkers for cancer diagnosis...
Developability assessment is a broad term covering the evaluation of potential therapeutic candidates’ drug-like properties, manufacturability and safety profile. It is important to carry out this assessment as early as possible in the pre-clinical stage development to select the candidate with the most stable profile. This can minimise the risks…
Returning to Central London for the 14th year, SMi’s Controlled Release Delivery conference will take place on the 3rd & 4th of April 2017...
Christian Andersson, Product Development Manager at Takara Bio discusses hiPS-derived beta cells, which offer an unprecedented opportunity for diabetes research to model human physiology and ‘diseases in a dish’. Christian looks into the potential for new discoveries for diabetes and other metabolic diseases...
Quotient Clinical announces that it has acquired QS Pharma from Charles River Laboratories International, Inc...
Charles River Laboratories has provided a progress update related to its support of Moderna Therapeutics’ nonclinical discovery and development efforts...
Drug developers sometimes think of imaging as an emerging discipline, full of esoteric technologies of marginal relevance to real-world clinical drug development. In fact, the opposite is true: imaging measurements (imaging biomarkers) are used daily in drug development and in personalised medicine. They assess target engagement and receptor occupancy in…
